Shi M, Bouwmeester H, Rietjens I, Strikwold M
Arch Toxicol. 2020; 94(8):2809-2827.
PMID: 32367273
PMC: 7395048.
DOI: 10.1007/s00204-020-02766-7.
Ahmad T, Valentovic M, Rankin G
Biochem Pharmacol. 2018; 153:196-204.
PMID: 29458047
PMC: 6148365.
DOI: 10.1016/j.bcp.2018.02.020.
Schaefer C, Tome M, Davis T
Fluids Barriers CNS. 2017; 14(1):32.
PMID: 29183383
PMC: 5706290.
DOI: 10.1186/s12987-017-0080-3.
Forcelli P, Turner J, Lee B, Olson T, Xie T, Xiao Y
Neuropharmacology. 2015; 101:46-56.
PMID: 26365569
PMC: 4681651.
DOI: 10.1016/j.neuropharm.2015.09.012.
Wolf C, Goldstein A, Poklis J, Poklis A
J Clin Lab Anal. 2014; 28(2):136-40.
PMID: 24395735
PMC: 6807644.
DOI: 10.1002/jcla.21657.
Illicit opioid intoxication: diagnosis and treatment.
Fareed A, Stout S, Casarella J, Vayalapalli S, Cox J, Drexler K
Subst Abuse. 2012; 5:17-25.
PMID: 22879747
PMC: 3411502.
DOI: 10.4137/SART.S7090.
Mechanism-based inactivation of cytochrome P450 2B6 by methadone through destruction of prosthetic heme.
Amunugama H, Zhang H, Hollenberg P
Drug Metab Dispos. 2012; 40(9):1765-70.
PMID: 22685215
PMC: 3422545.
DOI: 10.1124/dmd.112.045971.
Methadone and methadone metabolites in postmortem specimens.
Danielson T, Mozayani A, Sanchez L
Forensic Sci Med Pathol. 2009; 4(3):170-4.
PMID: 19291457
DOI: 10.1007/s12024-008-9039-7.
Interpretation of oral fluid tests for drugs of abuse.
Cone E, Huestis M
Ann N Y Acad Sci. 2007; 1098:51-103.
PMID: 17332074
PMC: 2700061.
DOI: 10.1196/annals.1384.037.
The acute disposition of (R)- and (s)-methadone in brain and lung of sheep.
Foster D, Upton R, Somogyi A, Grant C, Martinez A
J Pharmacokinet Pharmacodyn. 2005; 32(3-4):547-70.
PMID: 16284915
DOI: 10.1007/s10928-005-0056-9.
Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice.
Wang J, Ruan Y, Taylor R, Donovan J, Markowitz J, Devane C
Psychopharmacology (Berl). 2004; 173(1-2):132-8.
PMID: 14712343
DOI: 10.1007/s00213-003-1718-1.
Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.
Eap C, Buclin T, Baumann P
Clin Pharmacokinet. 2002; 41(14):1153-93.
PMID: 12405865
DOI: 10.2165/00003088-200241140-00003.
Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients.
Foster D, Somogyi A, Dyer K, White J, Bochner F
Br J Clin Pharmacol. 2000; 50(5):427-40.
PMID: 11069437
PMC: 2014413.
DOI: 10.1046/j.1365-2125.2000.00272.x.
Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4.
Foster D, Somogyi A, Bochner F
Br J Clin Pharmacol. 1999; 47(4):403-12.
PMID: 10233205
PMC: 2014231.
DOI: 10.1046/j.1365-2125.1999.00921.x.
Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts.
de Vos J, Geerlings P, van den Brink W, Ufkes J, van Wilgenburg H
Eur J Clin Pharmacol. 1995; 48(5):361-6.
PMID: 8641323
DOI: 10.1007/BF00194951.
The metabolism of methadone by cultured mammalian cells.
Will P, NOTEBOOM W
Experientia. 1978; 34(2):217-9.
PMID: 203475
DOI: 10.1007/BF01944687.
